Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Med Chem ; 62(3): 1274-1290, 2019 02 14.
Artículo en Inglés | MEDLINE | ID: mdl-30633509

RESUMEN

The clinical evidence for the success of tyrosine kinase inhibitors in combination with microtubule-targeting agents prompted us to design and develop single agents that possess both epidermal growth factor receptor (EGFR) kinase and tubulin polymerization inhibitory properties. A series of 6-aryl/heteroaryl-4-(3',4',5'-trimethoxyanilino)thieno[3,2- d]pyrimidine derivatives were discovered as novel dual tubulin polymerization and EGFR kinase inhibitors. The 4-(3',4',5'-trimethoxyanilino)-6-( p-tolyl)thieno[3,2- d]pyrimidine derivative 6g was the most potent compound of the series as an antiproliferative agent, with half-maximal inhibitory concentration (IC50) values in the single- or double-digit nanomolar range. Compound 6g bound to tubulin in the colchicine site and inhibited tubulin assembly with an IC50 value of 0.71 µM, and 6g inhibited EGFR activity with an IC50 value of 30 nM. Our data suggested that the excellent in vitro and in vivo profile of 6g may be derived from its dual inhibition of tubulin polymerization and EGFR kinase.


Asunto(s)
Diseño de Fármacos , Receptores ErbB/antagonistas & inhibidores , Microtúbulos/efectos de los fármacos , Pirimidinas/química , Pirimidinas/farmacología , Apoptosis/efectos de los fármacos , Ciclo Celular/efectos de los fármacos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Colchicina/metabolismo , Evaluación Preclínica de Medicamentos , Activación Enzimática , Células HeLa , Humanos , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Poli(ADP-Ribosa) Polimerasas/metabolismo , Polimerizacion , Especies Reactivas de Oxígeno/metabolismo , Tubulina (Proteína)/metabolismo , Receptor 2 de Factores de Crecimiento Endotelial Vascular/antagonistas & inhibidores
2.
Arch Pharm (Weinheim) ; 349(8): 638-50, 2016 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-27328401

RESUMEN

The synthesis of different compounds with a quinazolinone, quinazolinthione, or quinazolinimine skeleton and their in vitro biological evaluation as inhibitors of inducible and neuronal nitric oxide synthase (iNOS and nNOS) isoforms are described. These derivatives were obtained from substituted 2-aminobenzylamines, using diverse cyclization procedures. Furthermore, the diamines were synthesized by two routes: A conventional pathway and an efficient one-pot synthesis in a continuous-flow hydrogenator. The structures of these heterocycles were confirmed by (1) H and (13) C nuclear magnetic resonance and high-resolution mass spectroscopy data. The structure-activity relationships of the target molecules are discussed in terms of the effects of both the R radical and the X heteroatom in the 2-position. In general, the assayed compounds behave as better iNOS than nNOS inhibitors, with the quinazolinone 11e being the most active inhibitor of all tested compounds and the most iNOS/nNOS selective one.


Asunto(s)
Inhibidores Enzimáticos/síntesis química , Inhibidores Enzimáticos/farmacología , Óxido Nítrico Sintasa de Tipo II/antagonistas & inhibidores , Óxido Nítrico Sintasa de Tipo I/antagonistas & inhibidores , Quinazolinas/farmacología , Quinazolinonas/farmacología , Tionas/farmacología , Diseño de Fármacos , Inhibidores Enzimáticos/química , Quinazolinas/síntesis química , Quinazolinas/química , Quinazolinonas/síntesis química , Quinazolinonas/química , Ensayo de Unión Radioligante , Relación Estructura-Actividad , Tionas/síntesis química , Tionas/química
3.
Magn Reson Chem ; 54(10): 793-799, 2016 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-27173052

RESUMEN

The (1) H and (13) C NMR resonances of seventeen N-alkyl and aryl-N'-[3-hydroxy-3-(2-nitro-5-substitutedphenyl)propyl]-thioureas and ureas (1-17), and seventeen N-alkyl or aryl-N'-[3-(2-amino-5-substitutedphenyl)-3-hydroxypropyl]-thioureas and ureas (18-34), designed as NOS inhibitors, were assigned completely using the concerted application of one- and two-dimensional experiments (DEPT, HSQC and HMBC). NOESY studies confirm the preferred conformation of these compounds. Copyright © 2016 John Wiley & Sons, Ltd.


Asunto(s)
Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/farmacología , Óxido Nítrico Sintasa/antagonistas & inhibidores , Tiourea/análogos & derivados , Tiourea/química , Urea/análogos & derivados , Urea/química , Espectroscopía de Resonancia Magnética con Carbono-13/normas , Inhibidores Enzimáticos/síntesis química , Estructura Molecular , Óxido Nítrico Sintasa/metabolismo , Espectroscopía de Protones por Resonancia Magnética/normas , Estándares de Referencia , Tiourea/síntesis química , Tiourea/farmacología , Urea/síntesis química , Urea/farmacología
5.
ChemMedChem ; 10(5): 874-82, 2015 May.
Artículo en Inglés | MEDLINE | ID: mdl-25801086

RESUMEN

Herein we describe the synthesis of a new family of kynurenamine derivatives with a urea or thiourea moiety, together with their in vitro biological evaluation as inhibitors of both neuronal and inducible nitric oxide synthases (nNOS and iNOS, respectively), enzymes responsible for the biogenesis of NO. These compounds were synthesized from a 5-substituted-2-nitrophenyl vinyl ketone scaffold in a five-step procedure with moderate to high chemical yields. In general, the assayed compounds show greater inhibition of iNOS than of nNOS, with 1-[3-(2-amino-5-chlorophenyl)-3-oxopropyl]-3-ethylurea (compound 5 n) being the most potent iNOS inhibitor in the series and the most iNOS/nNOS-selective compound. In this regard, we performed molecular modeling studies to propose a binding mode for this family of compounds to both enzymes and, thereby, to elucidate the differential molecular features that could explain the observed selectivity between iNOS and nNOS.


Asunto(s)
Diseño de Fármacos , Inhibidores Enzimáticos/farmacología , Kinuramina/farmacología , Óxido Nítrico Sintasa de Tipo II/antagonistas & inhibidores , Óxido Nítrico Sintasa de Tipo I/antagonistas & inhibidores , Urea/química , Animales , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/síntesis química , Inhibidores Enzimáticos/química , Células Endoteliales de la Vena Umbilical Humana/efectos de los fármacos , Células Endoteliales de la Vena Umbilical Humana/metabolismo , Humanos , Kinuramina/análogos & derivados , Kinuramina/química , Masculino , Modelos Moleculares , Estructura Molecular , Óxido Nítrico/análisis , Óxido Nítrico Sintasa de Tipo I/metabolismo , Óxido Nítrico Sintasa de Tipo II/metabolismo , Ratas , Ratas Wistar , Relación Estructura-Actividad , Urea/análogos & derivados
6.
Eur J Med Chem ; 81: 394-407, 2014 Jun 23.
Artículo en Inglés | MEDLINE | ID: mdl-24858544

RESUMEN

The combination of two pharmacophores into a single molecule represents one of the methods that can be adopted for the synthesis of new anticancer molecules. A series of novel antiproliferative agents designed by a pharmacophore hybridization approach, combining the arylcinnamide skeleton and an α-bromoacryloyl moiety, was synthesized and evaluated for its antiproliferative activity against a panel of seven human cancer cell lines. In addition, the new derivatives were also active on multidrug-resistant cell lines over-expressing P-glycoprotein. The biological effects of various substituents on the N-phenyl ring of the benzamide portion were also described. In order to study the possible mechanism of action, we observed that 4p slightly increased the Reactive Oxygen Species (ROS) production in HeLa cells, but, more importantly, a remarkable decrease of intracellular reduced glutathione content was detected in treated cells compared with controls. These results were confirmed by the observation that only thiol-containing antioxidants were able to significantly protect the cells from induced cell death. Altogether our results indicate that the new derivatives are endowed with good anticancer activity in vitro, and their properties may result in the development of new cancer therapeutic strategies.


Asunto(s)
Antineoplásicos/síntesis química , Antineoplásicos/farmacología , Cinamatos/farmacología , Diseño de Fármacos , Antineoplásicos/química , Ciclo Celular/efectos de los fármacos , Muerte Celular/efectos de los fármacos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Cinamatos/síntesis química , Cinamatos/química , Relación Dosis-Respuesta a Droga , Ensayos de Selección de Medicamentos Antitumorales , Células HT29 , Células HeLa , Humanos , Leucocitos Mononucleares/efectos de los fármacos , Células MCF-7 , Estructura Molecular , Especies Reactivas de Oxígeno/metabolismo , Relación Estructura-Actividad
7.
Bioorg Med Chem ; 21(14): 4132-42, 2013 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-23735830

RESUMEN

In a preliminary article, we reported a series of 4,5-dihydro-1H-pyrazole derivatives as neuronal nitric oxide synthase (nNOS) inhibitors. Here we present the data about the inhibition of inducible nitric oxide synthase (iNOS) of these compounds. In general, we can confirm that these pyrazoles are nNOS selective inhibitors. In addition, taking these compounds as a reference, we have designed and synthesized a series of new derivatives by modification of the heterocycle in 1-position, and by introduction of electron-donating or electron-withdrawing substituents in the aromatic ring. These derivatives have been evaluated as nNOS and iNOS inhibitors in order to identify new compounds with improved activity and selectivity. Compound 3r, with three methoxy electron-donating groups in the phenyl moiety, is the most potent nNOS inhibitor, showing good selectivity nNOS/iNOS.


Asunto(s)
Inhibidores Enzimáticos/síntesis química , Inhibidores Enzimáticos/farmacología , Óxido Nítrico Sintasa de Tipo II/antagonistas & inhibidores , Óxido Nítrico Sintasa de Tipo I/antagonistas & inhibidores , Acilación , Animales , Sitios de Unión , Relación Dosis-Respuesta a Droga , Activación Enzimática/efectos de los fármacos , Humanos , Concentración 50 Inhibidora , Modelos Moleculares , Estructura Molecular , Pirazoles/síntesis química , Pirazoles/química , Pirazoles/farmacología , Relación Estructura-Actividad
8.
Magn Reson Chem ; 50(7): 515-22, 2012 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-22693150

RESUMEN

The (1) H and (13) C NMR resonances of twenty-seven 2,2-dimethyl-5-(2-nitrophenyl-5-substituted)-2,3-dihydro-1,3,4-thiadiazoles, and twenty-seven 3-acyl-5-(2-amino-5-substituted)-2,2-dimethyl-2,3-dihydro-1,3,4-thiadiazoles were assigned completely using the concerted application of one-dimensional and two-dimensional experiments (DEPT, HMQC and HMBC). NOESY experiments, X-ray crystallography and conformational analysis confirm the preferred conformation of these compounds.


Asunto(s)
Tiadiazoles/química , Espectroscopía de Resonancia Magnética/normas , Estructura Molecular , Estándares de Referencia
9.
Magn Reson Chem ; 50(1): 58-61, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-22259186

RESUMEN

The (13) C NMR resonances of 19 1-acyl-3-(2-nitro-5-substitutedphenyl)-4,5-dihydro-1H-pyrazoles, and 19 1-acyl-3-(2-amino-5-substituted)-4,5-dihydro-1H-pyrazoles, were completely assigned using the concerted application of one- and two-dimensional NMR experiments (DEPT, gs-HSQC and gs-HMBC).


Asunto(s)
Pirazoles/química , Isótopos de Carbono , Espectroscopía de Resonancia Magnética/normas , Pirazoles/síntesis química , Estándares de Referencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA